← All trials
NCT06052059
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2023
- Primary completion
- Nov 21, 2026
- Completion date
- Dec 17, 2029
- First posted
- Sep 25, 2023
- Last posted
- Dec 28, 2023
- Enrollment
- 1020
- Arms / groups
- 11 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.